Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH): AST2303 tablets receive approval for drug clinical trials.

Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) announced that the company recently received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, approving the clinical trial of AST2303 tablets in adult patients with advanced non-small cell lung cancer carrying the EGFR C797S mutation. The announcement states that AST2303 tablets (ABK3376 tablets) are a highly selective and brain-permeable new generation EGFR oral small molecule inhibitor that can effectively inhibit the EGFRC797S mutation.